Share Twitter LinkedIn Facebook Email Roy S. Herbst, MD, PhD, shares his thoughts on whether to continue pemetrexed maintenance after successful treatment of the patient with carboplatin / pemetrexed / embrolizumab.
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
